Iohexol Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution
Available Strengths: 240 mg/mL, 300 mg/mL, 350 mg/mL, 140 mg/mL
Reference Brands: Omnipaque(US & EU)
Category:
Contrast Agent
Iohexol injectable solution is a contrast agent that enhances X-ray and CT imaging by increasing vascular and tissue radiopacity. It provides clear visualization of blood vessels, organs, and tissues, aiding in accurate diagnosis. Benefits include improved imaging quality, safety, rapid excretion, and support for effective disease detection and assessment.
Iohexol Injectable Solution is available in Injectable Solution
and strengths such as 240 mg/mL, 300 mg/mL, 350 mg/mL, 140 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Iohexol Injectable Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Iohexol Injectable Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Iohexol injectable solution, marketed as Omnipaque, is approved in the US by the FDA and in the EU via EMA for use as a contrast agent in diagnostic imaging. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety, efficacy, and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and broad global availability, enabling precise imaging for effective diagnosis and treatment planning worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing